X
Xinyue Chen
Researcher at Capital Medical University
Publications - 4
Citations - 143
Xinyue Chen is an academic researcher from Capital Medical University. The author has contributed to research in topics: HBeAg & HBsAg. The author has an hindex of 4, co-authored 4 publications receiving 112 citations.
Papers
More filters
Journal ArticleDOI
Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
Rong Fan,Jian Sun,Quan Yuan,Qing Xie,Xuefan Bai,Qin Ning,Jun Cheng,Yanyan Yu,Junqi Niu,Guangfeng Shi,Hao Wang,Deming Tan,Mobin Wan,Shijun Chen,Min Xu,Xinyue Chen,Hong Tang,Jifang Sheng,Fengmin Lu,Jidong Jia,Hui Zhuang,Ningshao Xia,Jinlin Hou +22 more
TL;DR: Baseline anti-HBc titre is a useful predictor of Peg-IFN and NUC therapy efficacy in HBeAg-positive CHB patients, which could be used for optimising the antiviral therapy of CHB.
Journal ArticleDOI
Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study.
Di Wu,Peng Wang,Meifang Han,Yongping Chen,Xinyue Chen,Qi Xia,Weiming Yan,Xiaoyang Wan,Chuanlong Zhu,Qing Xie,Jiaji Jiang,Lai Wei,Deming Tan,Xiaoguang Dou,Yanyan Yu,Jinlin Hou,Xiaoping Luo,Qin Ning +17 more
TL;DR: For ETV-suppressed patients, particularly those with low baseline HBsAg levels, combination therapy with IFN and other immunomodulators may enhanceHBsAg loss, while successful response correlates with partial restoration of NK cells and Tregs.
Journal ArticleDOI
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
Lai Wei,Tao Han,Dongliang Yang,Jeong Heo,Jia Shang,Jun Cheng,Xinyue Chen,Qing Xie,Ju Hyun Kim,R. Kalmeijer,Sivi Ouwerkerk-Mahadevan,Eva Hoeben,Oliver Lenz,Thierry Verbinnen,Rekha Sinha,Mengchun Li,Jane Scott,Monika Peeters,James Witek +18 more
TL;DR: This study evaluated the efficacy, pharmacokinetics, safety, and tolerability of simeprevir plus peginterferon alpha‐2a and ribavirin in HCV GT1‐infected, treatment‐naïve, Asian patients with compensated liver disease.
Journal ArticleDOI
The role of peginterferon in nucleos(t)ide-analogue-treated chronic hepatitis B patients: A review of published literature.
TL;DR: In HBeAg‐negative NA‐treated patients, add‐on PegIFN therapy achieves higher, albeit modest, HBsAg loss rates compared with continued NA monotherapy and offers the opportunity for NA‐ treated patients to achieve the inactive carrier state.